ENVALITH
帝国通信工業株式会社 logo

Teikoku Tsushin Kogyo Co., Ltd.

6763・Prime Market・Electric Appliances

Official website
帝国通信工業株式会社 logo
Teikoku Tsushin Kogyo Co., Ltd.6763

Business

Teikoku Tsushin Kogyo Co., Ltd. (brand name: NOBLE) is an electronic components specialist founded in 1944, with Variable Resistors, Fixed Resistors, Sensors, and Front Operation Block (ICB) as its core products. Under a group structure of 16 domestic and overseas companies, it operates overseas production sites in Thailand, China, and Vietnam, and has sales subsidiaries in Singapore, the United States, Hong Kong, China, and elsewhere. Its main customers span a wide range of fields including automotive electronics, AV equipment, household appliances, medical/healthcare, and industrial equipment, with the Electronic Components segment accounting for approximately 97% of net sales. Listed on the Prime Market of the Tokyo Stock Exchange.

Business Model

The Group's source of competitive advantage lies in its integrated production system that internalizes resistive element technology, molding and decoration technology, press technology, and screen printing technology. It generates revenue through two pillars: custom products (such as ICB) developed through co-creative specification design from the customer's initial design stage, and general-purpose discrete products. Domestically, the company sells directly, while overseas sales are handled by regional sales subsidiaries. Capital expenditures and R&D expenses are self-funded through operating cash flow, and the company maintains a sound financial structure with effectively zero interest-bearing debt.

Company Strengths

The company possesses in-house resistive element technology, decorative molding technology, press technology, and screen printing technology, and has built a production system capable of handling materials, processing, and assembly on an integrated basis. This system enables the development and mass production of custom products that co-create specifications with customers from the early design stage, forming an entry barrier that is difficult for competitors to replicate in a short period of time.

As of the end of FY2026 (ending March 2026), interest-bearing debt stood at ¥46 million (borrowings from non-consolidated subsidiaries only), the equity ratio was 82.5%, and cash and cash equivalents amounted to ¥9,158 million. The company has the financial strength to fund capital expenditures, R&D expenses, and shareholder returns entirely through operating cash flow, maintaining financial soundness even during phases of large-scale investment.

The company has already achieved mass production of bioelectrodes used for electrocardiogram, electroencephalogram, and electromyogram measurements, and has a track record of manufacturing in the medical and healthcare field. Furthermore, it plans to mass-produce POCT biosensors (for sodium and potassium measurement) in the near future, and has positioned the establishment of electrochemical sensor technology as a key growth pillar in its next medium-term management plan.

ENVALITH's Perspective

Operating profit for FY2026 (ending March 2026) was ¥1,158 million (down 30.4% year on year), and the operating profit margin declined to 6.7% (from 9.9% in the prior period). Cost of sales increased to ¥12,198 million (from ¥11,461 million in the prior period), worsening the gross profit margin to 29.3% (from 31.7% in the prior period), while SG&A expenses also increased to ¥3,900 million (from ¥3,666 million in the prior period). R&D expenses expanded to ¥610 million (from ¥519 million in the prior period), and employee salaries also increased. As external factors, surging energy prices, difficulties in procuring raw materials, and rising logistics costs squeezed profit margins. Questions remain about the feasibility of the recovery scenario toward the FY2027 (ending March 2027) operating profit forecast of ¥1,500 million (up 29.5% year on year).

Expenditure on acquisition of property, plant and equipment for FY2026 (ending March 2026) surged to ¥3,237 million (from ¥867 million in the prior period), with construction in progress ballooning from ¥206 million to ¥2,856 million. Investing cash flow resulted in an outflow of ¥2,366 million (versus an inflow of ¥228 million in the prior period), and investment expenditure exceeding operating cash flow (¥1,934 million) pushed free cash flow into deficit. Cash and cash equivalents decreased by ¥1,906 million, from ¥11,064 million to ¥9,158 million. Cash outflows are expected to continue while the head office building reconstruction, targeted for completion in FY2027, proceeds, and attention should be paid to the timeline for investment recovery and the impact on the company's finances.

The earnings forecast for FY2027 (ending March 2027) calls for net sales of ¥18,000 million (up 4.3% year on year), operating profit of ¥1,500 million (up 29.5%), and net income attributable to owners of parent of ¥1,400 million (up 9.9%). The assumed exchange rate is US$1 = ¥150. Growth drivers cited include expansion in the medical and healthcare market, AI-related products, and product deployment for the infrastructure market. On the other hand, external factors such as the risk of a Strait of Hormuz blockade amid escalating tensions in the Middle East, surging crude oil and naphtha prices, the Trump administration's diplomatic policies, and a slowdown in the Chinese economy continue to pose downside risks. Attention should also be paid to the timing of realization of management efficiency gains from the planned absorption-type merger of consolidated subsidiary Iida Teitsu Co., Ltd. in July 2026 (a subsequent event).

Growth Strategy

Under the "Medium-Term Management Plan 2030," the company is advancing the establishment of new business domains in medical, sensors, AI, and infrastructure applications

Mass production of electrodes for EMG, ECG, and EEG measurement has already been achieved. The company plans to soon commence mass production of POCT biosensors (sodium and potassium measurement), and is expanding electrochemical sensor technology into the agribusiness and infrastructure businesses. Joint research with universities is being actively promoted. In FY2026 (ending March 2026), sales for the medical and healthcare markets performed well, and this is positioned as a key growth pillar in the next medium-term plan, Plan 2030.

The company is accelerating development of automotive products such as capacitive-type sensors, and promoting sales expansion of various sensors including contact sensors. Increasing HEV demand and progress in in-vehicle electronics adoption serve as tailwinds for the market environment. In FY2026 (ending March 2026), sales for the automotive electronics market performed well, with Mechanical Components achieving a significant revenue increase of 20.3% year on year.

The company is advancing the rebuilding of its head office building, which will embody sustainability by combining R&D and head office functions. In FY2026 (ending March 2026), construction in progress surged to ¥2,856 million, and expenditures for acquisition of property, plant and equipment totaled ¥3,237 million. The new R&D building aims to enhance development capabilities and accelerate mass production.

Against the backdrop of expanding semiconductor demand related to generative AI, the company has positioned product rollout for AI-related and infrastructure markets as a growth driver in the first year (fiscal 2026) of the "Medium-Term Management Plan 2030." Improvements in element technology through research on ink and printing methods will form the foundation for opening up new markets.

Resolved at the Board of Directors meeting on May 12, 2026, the company will implement an absorption-type merger with the effective date of merger scheduled for July 1, 2026. The aim is to create and maximize synergies through effective utilization of management resources and improved management efficiency, thereby strengthening the management foundation.

Last updated: July 19, 2026